Literature DB >> 22944532

225Ac and 223Ra production via 800 MeV proton irradiation of natural thorium targets.

J W Weidner1, S G Mashnik, K D John, B Ballard, E R Birnbaum, L J Bitteker, A Couture, M E Fassbender, G S Goff, R Gritzo, F M Hemez, W Runde, J L Ullmann, L E Wolfsberg, F M Nortier.   

Abstract

Cross sections for the formation of (225,227)Ac, (223,225)Ra, and (227)Th via the proton bombardment of natural thorium targets were measured at a nominal proton energy of 800 MeV. No earlier experimental cross section data for the production of (223,225)Ra, (227)Ac and (227)Th by this method were found in the literature. A comparison of theoretical predictions with the experimental data shows agreement within a factor of two. Results indicate that accelerator-based production of (225)Ac and (223)Ra is a viable production method. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22944532     DOI: 10.1016/j.apradiso.2012.07.003

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  9 in total

1.  Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.

Authors:  Nikki A Thiele; Justin J Wilson
Journal:  Cancer Biother Radiopharm       Date:  2018-06-11       Impact factor: 3.099

2.  A Radium-223 microgenerator from cyclotron-produced trace Actinium-227.

Authors:  Diane S Abou; Juile Pickett; John E Mattson; Daniel L J Thorek
Journal:  Appl Radiat Isot       Date:  2016-11-04       Impact factor: 1.513

Review 3.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

Review 4.  Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Authors:  Rubel Chakravarty; Cerise M Siamof; Ashutosh Dash; Weibo Cai
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-08-20

5.  Separation of 103Ru from a proton irradiated thorium matrix: A potential source of Auger therapy radionuclide 103mRh.

Authors:  Tara Mastren; Valery Radchenko; Philip D Hopkins; Jonathan W Engle; John W Weidner; Roy Copping; Mark Brugh; F Meiring Nortier; Eva R Birnbaum; Kevin D John; Michael Ernst-Heinrich Fassbender
Journal:  PLoS One       Date:  2017-12-22       Impact factor: 3.240

Review 6.  A random walk approach to estimate the confinement of α-particle emitters in nanoparticles for targeted radionuclide therapy.

Authors:  Uwe Holzwarth; Isaac Ojea Jimenez; Luigi Calzolai
Journal:  EJNMMI Radiopharm Chem       Date:  2018-05-30

Review 7.  An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth.

Authors:  Alfred Morgenstern; Christos Apostolidis; Clemens Kratochwil; Mike Sathekge; Leszek Krolicki; Frank Bruchertseifer
Journal:  Curr Radiopharm       Date:  2018

8.  ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.

Authors:  C Kratochwil; F L Giesel; F Bruchertseifer; W Mier; C Apostolidis; R Boll; K Murphy; U Haberkorn; A Morgenstern
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-29       Impact factor: 9.236

Review 9.  Supply and Clinical Application of Actinium-225 and Bismuth-213.

Authors:  Alfred Morgenstern; Christos Apostolidis; Frank Bruchertseifer
Journal:  Semin Nucl Med       Date:  2020-02-21       Impact factor: 4.446

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.